Zhitong Financial App News, Xiansheng Pharmaceutical (02096.HK) announced that on December 19, 2025, the group subsidiary Jiangsu Xiansheng Zaiming Pharmaceutical Co., Ltd. (Jiangsu Zaiming) and Ipsen Pharma SAS. (Euronext listing code: IPN; ADR transaction code: IPSEY) (Ipsen) signed an exclusive license agreement. Under the terms of the agreement, Ipsen will obtain exclusive global development, production and commercialization rights for SIM0613, an antibody-drug conjugate (ADC) targeting LRRC15 developed by Jiangsu Zaiming, in regions outside of Greater China.

Zhitong Financial App News, Xiansheng Pharmaceutical (02096.HK) announced that on December 19, 2025, the group subsidiary Jiangsu Xiansheng Zaiming Pharmaceutical Co., Ltd. (Jiangsu Zaiming) and Ipsen Pharma SAS. (Euronext listing code: IPN; ADR transaction code: IPSEY) (Ipsen) signed an exclusive license agreement. Under the terms of the agreement, Ipsen will obtain exclusive global development, production and commercialization rights for SIM0613, an antibody-drug conjugate (ADC) targeting LRRC15 developed by Jiangsu Zaiming, in regions outside of Greater China.